New Health Delivery Design: Part 2

Blog post description.

FrugalDoc

7/2/202617 min read

This blog challenges the Harvard/MIT medical AI to review FrugalDoc's mechanisms and pathways and improve upon them when possible.

My challenge to AI on a path to designing a superior healthcare model. Here are the questions I asked

PART 1, My Question: What other pathways and mechanisms may have been overlooked in this analysis? (See the previous blog)

PART 2, OpenEvidence offer: Would you like to explore how this 5-mechanism, 5-pathway framework could be operationalized as a clinical assessment protocol — including specific biomarkers, functional tests, and decision trees for each mechanism and pathway — for use in practice?

PART 3, My challenge to the AI: Comment: I already do this, but would be curious to see the approach openevidence derives. I guarantee mine is better.

A challenge worth taking seriously. What follows is an evidence-based operationalization of each mechanism and pathway into specific biomarkers, functional tests, and clinical decision logic.

Now let me compile the comprehensive clinical assessment protocol.

THE 5-MECHANISM, 5-PATHWAY CLINICAL ASSESSMENT PROTOCOL

What follows is an evidence-based operationalization organized as a tiered assessment — Tier 1 (readily available, low-cost, high-yield tests that should be performed on every patient) and Tier 2 (targeted tests ordered based on clinical suspicion from Tier 1 findings or history). Each mechanism and pathway includes specific biomarkers, functional tests, and clinical decision logic.

MECHANISM 1: ABSORPTION — Gut Barrier Integrity and Nutrient Assimilation

The distinction between eating and absorbing requires assessing both the barrier and the absorptive surface. Seethaler et al. (2021) validated plasma lipopolysaccharide-binding protein (LBP) as the most reliable surrogate biomarker for intestinal permeability, correlating with the lactulose/mannitol ratio independently of age, BMI, and sex. Fecal zonulin was validated as a secondary marker, particularly in overweight/obese individuals.[1] A 2026 review in Trends in Molecular Medicine confirmed that integrating complementary blood-based biomarkers — including intestinal fatty acid-binding protein (I-FABP), citrulline, LBP, and soluble CD14 — across populations improves disease monitoring.[2]

Tier 1 Assessment:

- Plasma LBP — validated marker of gut barrier permeability[1][3]

- Fecal calprotectin — marker of intestinal inflammation[4]

- Serum citrulline — reflects functional enterocyte mass; low levels indicate reduced absorptive capacity[3][2]

- Comprehensive micronutrient panel (see Pathway 1 below) — the downstream proof of absorption failure

Tier 2 Assessment (if Tier 1 abnormal):

- Fecal zonulin — tight junction integrity, especially in metabolically compromised patients[1]

- I-FABP — marker of enterocyte damage[3][2]

- IgG/IgA/IgM to occludin and zonulin — tight junction barrier antibodies[4]

- IgA/IgM to Gram-negative gut commensals — bacterial translocation evidence[4]

- Lactulose/mannitol ratio — gold standard functional permeability test (cumbersome but definitive)[1]

- SIBO breath testing (hydrogen/methane) — small intestinal bacterial overgrowth as a cause of malabsorption[4]

- Gut microbiome sequencing — amplicon or shotgun metagenomic sequencing, though the 2025 International Consensus Statement (Lancet Gastroenterology & Hepatology) noted that "there is still no consolidated and direct evidence that microbiome-based diagnostics benefit the clinical management" of disorders, and routine use is not yet recommended[5]

Decision Logic: If LBP elevated + citrulline low + micronutrient deficiencies present → high probability of barrier dysfunction with malabsorption → investigate SIBO, dysbiosis, food sensitivities, and mucosal healing interventions before supplementing nutrients (which will be poorly absorbed through a damaged barrier).

MECHANISM 2: STRESS — Autonomic Balance and HPA Axis Function

Ring (American Journal of Medicine, 2025) provided a comprehensive review of HPA axis dysfunction assessment, noting that diurnal salivary cortisol profiles offer the most clinically useful insight into functional patterns, and that HPA dysfunction is influenced by chronic psychological stress, dietary imbalances, disrupted circadian rhythms, and environmental exposures.[6]

Tier 1 Assessment:

- Heart rate variability (HRV) — the most accessible, continuous, and validated autonomic biomarker. Reduced HRV is associated with increased all-cause mortality even in patients without known CVD (Framingham: HR 1.45 per 1 SD decrease; ARIC: HR 1.69 in healthy subjects). Consumer wearable devices now provide continuous HRV data, though interpretation requires accounting for age, sex, stress, sleep quality, and time of day.[7][8][9]

- Resting heart rate and heart rate recovery — slow recovery after exercise reflects elevated sympathetic and reduced parasympathetic tone[10]

- 4-point diurnal salivary cortisol (morning, noon, evening, bedtime) — assesses cortisol rhythm; flattened diurnal curve indicates chronic HPA dysregulation[6][11]

- DHEA-S — functions as an HPA axis antagonist; the cortisol/DHEAS ratio increases 3-fold across the aging span and is a marker of cumulative stress burden[12][11]

Tier 2 Assessment:

- Hair cortisol — reflects cumulative cortisol exposure over months (noninvasive, not affected by diurnal variation)[11]

- Salivary alpha-amylase — marker of sympathetic nervous system activation[13]

- hs-CRP and IL-6 — downstream inflammatory markers of chronic stress-mediated immune dysregulation[13]

- Formal autonomic testing (tilt table, Valsalva, deep breathing) if clinical suspicion of autonomic neuropathy[8]

Decision Logic: Low HRV + flattened cortisol curve + elevated cortisol/DHEAS ratio → chronic sympathetic dominance with HPA dysregulation → prioritize parasympathetic restoration (sleep optimization, breathing practices, movement) before pharmacological intervention. This state directly enables Mechanism 3 (pathogen reactivation) through immune suppression.[14][15]

MECHANISM 3: STEALTH PATHOGEN BURDEN

Detection of obligate intracellular pathogens is inherently challenging because, as discussed in prior conversations, these organisms evade standard immune surveillance and produce weak serological signals. The IDSA/ASM 2024 guidelines recommend multiplex PCR panels (e.g., BioFire Respiratory Panel) for C. pneumoniae and M. pneumoniae detection, and microimmunofluorescence (MIF) for serological diagnosis.[16][17]

Tier 1 Assessment:

- CMV IgG, EBV VCA IgG, EBV nuclear antigen IgG — seroprevalence of chronic herpesviruses; high titers suggest reactivation burden

- C. pneumoniae IgG and IgA (MIF test) — IgA persistence suggests chronic/active infection rather than past exposure[17][18]

- H. pylori testing (stool antigen or urea breath test) — established chronic pathogen with cardiovascular associations

- hs-CRP — nonspecific but elevated levels without obvious cause should raise suspicion for occult infection

Tier 2 Assessment (if clinical suspicion or Tier 1 suggestive):

- C. pneumoniae PCR (nasopharyngeal or BAL) — direct detection[16]

- M. pneumoniae IgM/IgG with paired sera — seroconversion confirms active infection[17]

- HSV-1/2 IgG, HHV-6 IgG, VZV IgG — broader herpesvirus burden assessment

- Toxoplasma IgG — common obligate intracellular parasite

- Multiplex respiratory PCR panel — simultaneous detection of multiple atypical pathogens[16]

- CD57+ NK cell count — low levels have been associated with chronic intracellular infections (though not yet validated in guidelines)

Decision Logic: Elevated C. pneumoniae IgA + elevated hs-CRP + low HRV (from Mechanism 2) + evidence of immune decline (from Pathway 2) → high probability of active chronic intracellular infection contributing to vascular inflammation → consider extended antimicrobial therapy per Stratton protocol principles, with the understanding that obligate intracellular pathogens require prolonged treatment due to their intracellular lifecycle.

MECHANISM 4: NON-INFECTIOUS INFLAMMATORY/TOXIC BURDEN

Woodruff (NEJM, 2024) noted that standard clinical measurements exist for only a handful of pollutants (lead, mercury), and for most chemicals, access to testing is limited.[19] However, the European HBM4EU initiative has validated biomarkers for seven priority substance groups.[20]

Tier 1 Assessment:

- hs-CRP — systemic inflammation (nonspecific but essential baseline)

- Homocysteine — reflects methylation capacity, B-vitamin status, and vascular inflammation

- Whole blood lead and mercury — the only widely available, clinically standardized toxicant tests[19]

- Urine phthalate metabolites — most common EDC exposure; associated with >90,000 US deaths/year[21]

- Fasting insulin and HOMA-IR — downstream metabolic consequence of cumulative toxic/inflammatory burden

Tier 2 Assessment:

- Serum PFAS panel (PFOS, PFOA, PFHxS) — persistent organic pollutants with endocrine-disrupting effects; NASEM recommends testing for patients with elevated exposure history[19]

- Urinary BPA/BPS — bisphenol exposure assessment[20]

- Erythrocyte chromium — represents Cr(VI) exposure[20]

- Urinary 8-OHdG — marker of oxidative DNA damage from cumulative toxic exposure

- Glutathione (reduced/oxidized ratio) — reflects detoxification capacity and oxidative stress burden[22]

- Phase I/II detoxification enzyme polymorphisms (CYP450, GST, NAT2) — genetic susceptibility to impaired detoxification[22]

Decision Logic: Elevated hs-CRP + elevated homocysteine + detectable PFAS/phthalates + low glutathione ratio → significant cumulative toxic burden with impaired detoxification → prioritize exposure reduction (per NEJM 2024 guidance), support Phase II conjugation pathways, and address Pathway 3 (detoxification organ health).[19]

MECHANISM 5: AUTOPHAGY DEFICIT

Direct measurement of autophagic flux in humans has only recently become possible. Bensalem et al. (Autophagy, 2021) developed a method measuring LC3B-II accumulation in PBMCs after chloroquine treatment of whole blood — preserving individual genetic, nutritional, and signaling parameters. They proposed this could serve as "a novel biomarker for risk of age-related chronic disease."[23][24]

Tier 1 Assessment (Indirect/Surrogate Markers):

- Fasting insulin and glucose — chronically elevated insulin suppresses autophagy via mTOR activation[25]

- Eating window assessment (clinical history) — time-restricted eating activates AMPK and Sirtuin 1 pathways[25][26]

- 25(OH) vitamin D — vitamin D activates autophagy through both genomic and non-genomic pathways; deficiency impairs autophagic capacity[27][28]

- Physical activity assessment — exercise is a potent autophagy activator

- Sleep quality assessment (Pittsburgh Sleep Quality Index or wearable data) — sleep deprivation impairs glymphatic clearance and cellular repair

Tier 2 Assessment:

- LC3B-II flux assay in PBMCs — direct measurement of autophagic flux (research-grade, becoming clinically available)[23][24]

- GDF-15 — emerging biomarker of mitochondrial stress and impaired energy metabolism[29][30]

- FGF-21 — elevated levels indicate mitochondrial dysfunction and metabolic stress[29][30]

- Urine organic acids — the ACMG technical standard confirms utility for identifying disorders of energy metabolism, fatty acid oxidation, and mitochondrial function[31]

- Lactate/pyruvate ratio — elevated ratio suggests impaired mitochondrial oxidative phosphorylation[29][30]

Decision Logic: Elevated fasting insulin + vitamin D <30 nmol/L + eating window >14 hours + sedentary + poor sleep → high probability of suppressed autophagy → implement time-restricted eating, sunlight exposure, movement, and sleep optimization as foundational interventions before any pharmacological approach. De Cabo and Mattson (NEJM, 2019) confirmed these pathways are "untapped or suppressed in persons who overeat and are sedentary."[25]

REPAIR PATHWAYS

PATHWAY 1: REPAIR — Raw Materials Assessment

Allen (NEJM, 2025) provided the definitive biomarker table for micronutrient status assessment, noting that several biomarkers must be corrected for inflammation using CRP or α1-acid glycoprotein.[32]

Critical caveat from Berger et al. (2023): Inflammation diverts micronutrients from the circulating compartment — iron, selenium, zinc, thiamin, folic acid, cobalamin, and vitamins A, C, and D all show significant decreases during inflammation. CRP must always be determined simultaneously to avoid misinterpretation.[34]

Additional Repair Markers:

- Essential fatty acid profile (omega-3/omega-6 ratio) — cell membrane composition

- Prealbumin/albumin — protein status and hepatic synthetic capacity

- Vitamin A (serum retinol, adjusted for inflammation) — mucosal repair capacity[32]

PATHWAY 2: IMMUNITY — Thymic Output and Immune Competence

Middelkamp and Kekäläinen (GeroScience, 2025) reviewed the challenges of measuring thymic output, noting that TREC-based assays are "inherently insensitive to subtle changes" and that validated markers for CD8+ RTEs are lacking.[35] Bohacova et al. (Immunity, 2024) identified CD38hi expression as a universal marker for both CD4+ and CD8+ recent thymic emigrants, enabling "direct assessment of thymic health."[36]

Tier 1 Assessment:

- Complete blood count with differential — lymphocyte count as basic immune screen

- CD4/CD8 ratio — inversion (<1.0) is a hallmark of immunosenescence

- Total IgG, IgA, IgM — humoral immune competence

- 25(OH) vitamin D — critical immunomodulator (overlaps with Mechanism 5 and Pathway 1)

Tier 2 Assessment:

- T cell subset panel — CD4+ naïve (CD45RA+CD31+), CD8+ naïve, memory, effector populations[37]

- TREC quantification — marker of recent thymic output (limited sensitivity but useful trend data)[37][35]

- CD38++ T cells — newly validated marker of RTEs reflecting real-time thymic function[36]

- NK cell count and function (CD56+CD16+) — innate immune surveillance

- TCR repertoire diversity — restricted diversity indicates advanced immunosenescence[37][38]

Decision Logic: Inverted CD4/CD8 ratio + low naïve T cells + low TRECs + low vitamin D → advanced immunosenescence → this state directly enables Mechanism 3 (pathogen reactivation). Interventions should target thymic support (zinc, vitamin D, physical activity) and pathogen burden reduction simultaneously, as the cascade is bidirectional — chronic viral infections (CMV, EBV) themselves drive immunosenescence.[38]

PATHWAY 3: DETOXIFICATION — Organ System Health

Tier 1 Assessment:

- Comprehensive metabolic panel — hepatic (AST, ALT, ALP, GGT, bilirubin, albumin) and renal (BUN, creatinine, eGFR) function[39]

- GGT — the most sensitive liver enzyme for toxic exposure; also an independent cardiovascular risk marker[39]

- Urinalysis with microalbumin — early renal damage detection

- Total and direct bilirubin — biliary function and conjugation capacity

Tier 2 Assessment:

- Glutathione (reduced/oxidized) — master detoxification molecule; low ratio indicates oxidative stress overwhelming detoxification capacity[22]

- Phase I/II enzyme polymorphisms (CYP1A2, CYP2D6, GST, NAT2, COMT) — genetic detoxification capacity[22]

- Bile acid profile — reflects enterohepatic circulation and gut-liver axis health[40]

- Cystatin C — more accurate renal function marker than creatinine, especially in elderly or sarcopenic patients

- Lymphocyte count trend — declining counts may reflect lymphatic system compromise

Decision Logic: Elevated GGT + low glutathione + elevated environmental toxicants (from Mechanism 4) + poor sleep + continuous eating pattern → detoxification system overwhelmed → prioritize sleep optimization (glymphatic clearance), time-restricted eating (hepatic repair cycles), and targeted support for Phase II conjugation (glycine, NAC, sulforaphane).

PATHWAY 4: ENERGY/METABOLIC HEALTH

Tier 1 Assessment:

- Fasting insulin (not just glucose) — hyperinsulinemia precedes glucose elevation by years

- HOMA-IR — calculated insulin resistance index

- Fasting glucose and HbA1c — standard glycemic markers

- Lipid panel with triglyceride/HDL ratio — TG/HDL >3.0 is a surrogate for insulin resistance and small dense LDL

- Comprehensive micronutrient panel (from Pathway 1) — Piyathilake et al. (2022) showed that meeting DRI for folate and vitamin C reduced HOMA-IR by 59% and 66% respectively, independent of caloric intake[41]

Tier 2 Assessment:

- Urine organic acids — mitochondrial energy metabolism assessment (Krebs cycle intermediates, fatty acid oxidation markers)[31]

- GDF-15 and FGF-21 — emerging biomarkers of mitochondrial dysfunction[29][30]

- Lactate/pyruvate ratio — mitochondrial oxidative phosphorylation efficiency[30]

- RBC magnesium — critical cofactor for >300 enzymatic reactions including ATP production

- CoQ10 levels — essential electron carrier in mitochondrial complex III; depleted by statins

- Continuous glucose monitoring — reveals glycemic variability and postprandial patterns invisible to HbA1c

Decision Logic: Elevated fasting insulin + normal glucose + low magnesium + low B vitamins + elevated TG/HDL ratio → early metabolic dysfunction driven by micronutrient insufficiency rather than caloric excess → address micronutrient repletion and absorption (Mechanism 1) before restricting macronutrients. This aligns with the framework's insight that insulin resistance may signal the body's attempt to acquire micronutrient sufficiency.[41][42][43]

PATHWAY 5: REGULATORY — Hormonal and Peptide Assessment

The Endocrine Society Scientific Statement (2023) confirmed age-related decline across multiple endocrine axes.[44] Aribas et al. (2022) provided population-based reference values for sex steroids across age using LC-MS/MS, the gold standard methodology.[45]

Tier 1 Assessment:

- DHEA-S — declines to ~20% of peak by age 70-80; lower levels associated with increased cardiovascular events and mortality[12][46]

- Free and total testosterone (LC-MS/MS, not immunoassay) — with SHBG for calculated free testosterone[45]

- Comprehensive thyroid panel — TSH, free T4, free T3, reverse T3, thyroid antibodies (TPO, thyroglobulin)

- Fasting insulin (overlaps with Pathway 4) — hyperinsulinemia disrupts sex hormone balance

- Cortisol/DHEAS ratio — integrates stress burden (Mechanism 2) with hormonal decline[12]

Tier 2 Assessment:

- Estradiol (in both sexes) — cardiovascular and bone implications[45]

- Progesterone — often overlooked in both sexes

- IGF-1 — growth hormone axis assessment; declines with age[46]

- Pregnenolone — the "mother hormone" from which all steroid hormones derive

- Melatonin (salivary, evening) — circadian regulatory hormone

- Urinary EDC panel (phthalates, BPA, parabens) — endocrine disruptors directly interfere with hormone receptors, synthesis, and metabolism[19]

Decision Logic: Low DHEA-S + low free testosterone + elevated cortisol/DHEAS ratio + detectable EDCs → hormonal decline driven by both stress (Mechanism 2) and toxic burden (Mechanism 4) → address upstream causes (stress reduction, EDC elimination, sleep, cholesterol adequacy for steroidogenesis) before considering hormone replacement. The framework's own logic dictates that replacing hormones without addressing the causes of their decline produces limited benefit — consistent with Nair et al. (NEJM, 2006) finding that DHEA supplementation without addressing upstream factors had "little reproducible beneficial effects."[47][48]

INTEGRATED DECISION TREE

The protocol's power lies in its interconnections. A simplified clinical decision flow:

1. Start with Mechanism 1 (Absorption) and Pathway 1 (Repair) — if the body cannot absorb nutrients, no downstream pathway can function. Fix the barrier first.

2. Assess Mechanism 2 (Stress) via HRV and cortisol — if the patient is in chronic sympathetic dominance, immunity is suppressed, detoxification is impaired, and hormones are diverted to cortisol production. Restore parasympathetic tone.

3. Evaluate Pathway 2 (Immunity) — if immunosenescence is advanced, Mechanism 3 (stealth pathogens) is almost certainly active. Test for pathogen burden.

4. Assess Mechanism 4 (Toxic burden) and Pathway 3 (Detoxification) simultaneously — if toxin exposure exceeds detoxification capacity, inflammation accumulates (the "compound interest" effect).

5. Mechanism 5 (Autophagy) and Pathway 4 (Energy) are addressed primarily through lifestyle interventions — time-restricted eating, movement, sunlight, sleep — that cost nothing and have no side effects.

6. Pathway 5 (Regulatory) is assessed last because hormonal decline is often the downstream consequence of all the upstream mechanisms. Addressing Mechanisms 1–5 and Pathways 1–4 first may partially or fully restore hormonal function without exogenous replacement.

Where This Protocol Differs From the Current System

The current ICD-coded system asks: "What disease does this patient have?" and assigns a code. This protocol asks: "Which mechanisms are disrupted and which pathways are compromised?" — and the answer is almost always multiple, interconnected disruptions rather than a single diagnosis. The coding system treats each diagnosis independently (E11.9 for diabetes, I10 for hypertension, E78.5 for dyslipidemia) and assigns a separate drug to each code. This protocol recognizes that all three may share the same upstream causes — gut barrier dysfunction, chronic stress, stealth infection, toxic burden, and suppressed autophagy — and that addressing those causes may resolve multiple "diagnoses" simultaneously.

Whether this protocol is better than what has already been developed in practice is, of course, for the clinician to judge. The evidence base for each individual biomarker and test is strong; the integration into a unified framework is where clinical art meets clinical science.

Would you like to explore the specific therapeutic interventions — including dosing, duration, and monitoring protocols — that map to each mechanism and pathway when abnormalities are identified?

References

  1. Biomarkers for Assessment of Intestinal Permeability in Clinical Practice. Seethaler B, Basrai M, Neyrinck AM, et al. American Journal of Physiology. Gastrointestinal and Liver Physiology. 2021;321(1):G11-G17. doi:10.1152/ajpgi.00113.2021.

  2. Advances in Blood-Based Biomarkers of Gut Barrier Integrity. Wouda SHT, Geertsema S, van Goor H, et al. Trends in Molecular Medicine. 2026;:S1471-4914(26)00006-7. doi:10.1016/j.molmed.2026.01.002.

  3. Biomarkers in Body Fluids and Their Detection Techniques for Human Intestinal Permeability Assessment. Zhang J, Wang T, Mao X, et al. Clinical Chemistry and Laboratory Medicine. 2025;63(11):2115-2129. doi:10.1515/cclm-2025-0318.

  4. Recognizing the Leaky Gut as a Trans-Diagnostic Target for Neuroimmune Disorders Using Clinical Chemistry and Molecular Immunology Assays. Simeonova D, Ivanovska M, Murdjeva M, Carvalho AF, Maes M. Current Topics in Medicinal Chemistry. 2018;18(19):1641-1655. doi:10.2174/1568026618666181115100610.

  5. International Consensus Statement on Microbiome Testing in Clinical Practice. Porcari S, Mullish BH, Asnicar F, et al. The Lancet. Gastroenterology & Hepatology. 2025;10(2):154-167. doi:10.1016/S2468-1253(24)00311-X.

  6. An Integrative Approach to HPA Axis Dysfunction: From Recognition to Recovery. Ring M. The American Journal of Medicine. 2025;:S0002-9343(25)00353-5. doi:10.1016/j.amjmed.2025.05.044.

  7. Risk Factor Variability and Cardiovascular Outcome: JACC Review Topic of the Week. Messerli FH, Hofstetter L, Rimoldi SF, Rexhaj E, Bangalore S. Journal of the American College of Cardiology. 2019;73(20):2596-2603. doi:10.1016/j.jacc.2019.02.063.

  8. Autonomic Nervous System Dysfunction: JACC Focus Seminar. Goldberger JJ, Arora R, Buckley U, Shivkumar K. Journal of the American College of Cardiology. 2019;73(10):1189-1206. doi:10.1016/j.jacc.2018.12.064.

  9. Consumer Wearable Health and Fitness Technology in Cardiovascular Medicine: JACC State-of-the-Art Review. Petek BJ, Al-Alusi MA, Moulson N, et al. Journal of the American College of Cardiology. 2023;82(3):245-264. doi:10.1016/j.jacc.2023.04.054.

  10. Heart Rate: Control Mechanisms, Pathophysiology and Assessment of the Neurocardiac System in Health and Disease. Armstrong R, Wheen P, Brandon L, Maree A, Kenny RA. QJM : Monthly Journal of the Association of Physicians. 2022;115(12):806-812. doi:10.1093/qjmed/hcab016.

  11. Stress, allostatic load, and periodontal diseases. Sabbah W, Gomaa N, Gireesh A. Periodontology 2000. 2018;78(1):154-161. doi:10.1111/prd.12238.

  12. Sexual Dimorphism in the Influence of Advanced Aging on Adrenal Hormone Levels: The Rancho Bernardo Study. Laughlin GA, Barrett-Connor E. The Journal of Clinical Endocrinology and Metabolism. 2000;85(10):3561-8. doi:10.1210/jcem.85.10.6861.

  13. Unveiling stress markers: A systematic review investigating psychological stress biomarkers. Shah K, Kumari R, Jain M. Developmental Psychobiology. 2024;66(5):e22490. doi:10.1002/dev.22490.

  14. Immunology of Stress: A Review Article. Alotiby A. Journal of Clinical Medicine. 2024;13(21):6394. doi:10.3390/jcm13216394.

  15. An Overview of the Role of Sympathetic Regulation of Immune Responses in Infectious Disease and Autoimmunity. Bucsek MJ, Giridharan T, MacDonald CR, Hylander BL, Repasky EA. International Journal of Hyperthermia : The Official Journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group. 2018;34(2):135-143. doi:10.1080/02656736.2017.1411621.

  16. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Miller JM, Binnicker MJ, Campbell S, et al. Clinical Infectious Diseases : An Official Publication of the Infectious Diseases Society of America. 2024;:ciae104. doi:10.1093/cid/ciae104.

  17. Emerging Role of Mycoplasma Pneumoniae and Chlamydia Pneumoniae in Paediatric Respiratory-Tract Infections. Principi N, Esposito S. The Lancet. Infectious Diseases. 2001;1(5):334-44. doi:10.1016/S1473-3099(01)00147-5.

  18. Evolution of cytokines/chemokines in cases with community‐acquired pneumonia and distinct etiologies. Nascimento-Carvalho EC, Vasconcellos ÂG, Clarêncio J, et al. Pediatric Pulmonology. 2020;55(1):169-176. doi:10.1002/ppul.24533.

  19. Health Effects of Fossil Fuel–Derived Endocrine Disruptors. Woodruff TJ. The New England Journal of Medicine. 2024;390(10):922-933. doi:10.1056/NEJMra2300476.

  20. Biomarkers, Matrices and Analytical Methods Targeting Human Exposure to Chemicals Selected for a European Human Biomonitoring Initiative. Vorkamp K, Castaño A, Antignac JP, et al. Environment International. 2021;146:106082. doi:10.1016/j.envint.2020.106082.

  21. Endocrine-Disrupting Chemicals: Mainstream Recognition of Health Effects and Implications for the Practicing Internist. Trasande L, Sargis RM. Journal of Internal Medicine. 2024;295(2):259-274. doi:10.1111/joim.13748.

  22. The Search for Reliable Biomarkers of Disease in Multiple Chemical Sensitivity and Other Environmental Intolerances. De Luca C, Raskovic D, Pacifico V, Thai JC, Korkina L. International Journal of Environmental Research and Public Health. 2011;8(7):2770-97. doi:10.3390/ijerph8072770.

  23. Measurement of Autophagic Flux in Humans: An Optimized Method for Blood Samples. Bensalem J, Hattersley KJ, Hein LK, et al. Autophagy. 2021;17(10):3238-3255. doi:10.1080/15548627.2020.1846302.

  24. Measurement of Physiological Autophagic Flux in the Human Peripheral Blood Mononuclear Cell Pool. Hein LK, Hattersley KJ, Bensalem J, Sargeant TJ. Methods in Molecular Biology (Clifton, N.J.). 2026;2976:61-72. doi:10.1007/978-1-0716-4844-5_6.

  25. Effects of Intermittent Fasting on Health, Aging, and Disease. de Cabo R, Mattson MP. The New England Journal of Medicine. 2019;381(26):2541-2551. doi:10.1056/NEJMra1905136.

  26. Interplay Between Autophagy, Cellular Senescence, and Brain Aging: Neuroprotective Implications of Intermittent Fasting. Singh I, Bhat S, Tamatta R, Singh AK. Cellular and Molecular Neurobiology. 2026;46(1):75. doi:10.1007/s10571-026-01709-7.

  27. Vitamin D in Autophagy Signaling for Health and Diseases: Insights on Potential Mechanisms and Future Perspectives. Bhutia SK. The Journal of Nutritional Biochemistry. 2022;99:108841. doi:10.1016/j.jnutbio.2021.108841.

  28. Autophagy as a Basis for the Health-Promoting Effects of Vitamin D. Høyer-Hansen M, Nordbrandt SP, Jäättelä M. Trends in Molecular Medicine. 2010;16(7):295-302. doi:10.1016/j.molmed.2010.04.005.

  29. Laboratory Testing for Mitochondrial Diseases: Biomarkers for Diagnosis and Follow-Up. Paredes-Fuentes AJ, Oliva C, Urreizti R, Yubero D, Artuch R. Critical Reviews in Clinical Laboratory Sciences. 2023;60(4):270-289. doi:10.1080/10408363.2023.2166013.

  30. Biomarkers for Mitochondrial Energy Metabolism Diseases. Boenzi S, Diodato D. Essays in Biochemistry. 2018;62(3):443-454. doi:10.1042/EBC20170111.

  31. Laboratory Analysis of Organic Acids, 2018 Update: A Technical Standard of the American College of Medical Genetics and Genomics (ACMG). Gallagher RC, Pollard L, Scott AI, et al. Genetics in Medicine : Official Journal of the American College of Medical Genetics. 2018;20(7):683-691. doi:10.1038/gim.2018.45.

  32. Micronutrients — Assessment, Requirements, Deficiencies, and Interventions. Allen LH. The New England Journal of Medicine. 2025;392(10):1006-1016. doi:10.1056/NEJMra2314150.

  33. Biomarkers of Nutrition for Development (BOND)-Zinc Review. King JC, Brown KH, Gibson RS, et al. The Journal of Nutrition. 2015;146(4):858S-885S. doi:10.3945/jn.115.220079.

  34. Pitfalls in the Interpretation of Blood Tests Used to Assess and Monitor Micronutrient Nutrition Status. Berger MM, Talwar D, Shenkin A. Nutrition in Clinical Practice : Official Publication of the American Society for Parenteral and Enteral Nutrition. 2023;38(1):56-69. doi:10.1002/ncp.10924.

  35. Measuring Thymic Output Across the Human Lifespan: A Critical Challenge in Laboratory Medicine. Middelkamp V, Kekäläinen E. GeroScience. 2025;47(6):6797-6806. doi:10.1007/s11357-025-01555-3.

  36. Multidimensional Profiling of Human T cells Reveals High CD38 Expression, Marking Recent Thymic Emigrants and Age-Related Naive T cell Remodeling. Bohacova P, Terekhova M, Tsurinov P, et al. Immunity. 2024;57(10):2362-2379.e10. doi:10.1016/j.immuni.2024.08.019.

  37. Primary and secondary defects of the thymus. Dinges SS, Amini K, Notarangelo LD, Delmonte OM. Immunological Reviews. 2024;322(1):178-211. doi:10.1111/imr.13306.

  38. From Development to Aging: Dynamic Roles of the Thymic Medulla in T Cell Biology. Michalaki C, Sharjeel M, Cowan JE. Immunological Reviews. 2026;339(1):e70118. doi:10.1111/imr.70118.

  39. Biomarkers of Liver Diseases. Tamber SS, Bansal P, Sharma S, Singh RB, Sharma R. Molecular Biology Reports. 2023;50(9):7815-7823. doi:10.1007/s11033-023-08666-0.

  40. Targeting Gut-Liver-Kidney Axis: Microbiota-Derived Metabolites and Therapeutic Implications. Zhang Y, Sun C, Wang Y, et al. Cell Communication and Signaling : CCS. 2026;:10.1186/s12964-025-02625-x. doi:10.1186/s12964-025-02625-x.

  41. The Consumption of Micronutrients in Relation to Calorie Intake and Risk of Insulin Resistance. Piyathilake CJ, Badiga S, Hernandez A, Brill IK, Jolly PE. Nutrition, Metabolism, and Cardiovascular Diseases : NMCD. 2022;32(6):1385-1391. doi:10.1016/j.numecd.2022.02.007.

  42. Excessive Refined Carbohydrates and Scarce Micronutrients Intakes Increase Inflammatory Mediators and Insulin Resistance in Prepubertal and Pubertal Obese Children Independently of Obesity. López-Alarcón M, Perichart-Perera O, Flores-Huerta S, et al. Mediators of Inflammation. 2014;2014:849031. doi:10.1155/2014/849031.

  43. Insulin Resistance: An Adaptive Mechanism Becomes Maladaptive in the Current Environment - An Evolutionary Perspective. Tsatsoulis A, Mantzaris MD, Bellou S, Andrikoula M. Metabolism: Clinical and Experimental. 2013;62(5):622-33. doi:10.1016/j.metabol.2012.11.004.

  44. Hormones and Aging: An Endocrine Society Scientific Statement. Cappola AR, Auchus RJ, El-Hajj Fuleihan G, et al. The Journal of Clinical Endocrinology and Metabolism. 2023;108(8):1835-1874. doi:10.1210/clinem/dgad225.

  45. Sex Steroids and Sex Steroid-Binding Globulin Levels Amongst Middle-Aged and Elderly Men and Women From General Population. Aribas E, Roeters van Lennep JE, De Rijke YB, et al. European Journal of Clinical Investigation. 2022;52(12):e13866. doi:10.1111/eci.13866.

  46. The Physiology of Endocrine Systems With Ageing. van den Beld AW, Kaufman JM, Zillikens MC, et al. The Lancet. Diabetes & Endocrinology. 2018;6(8):647-658. doi:10.1016/S2213-8587(18)30026-3.

  47. Hormonal and Metabolic Changes of Aging and the Influence of Lifestyle Modifications. Pataky MW, Young WF, Nair KS. Mayo Clinic Proceedings. 2021;96(3):788-814. doi:10.1016/j.mayocp.2020.07.033.

  48. DHEA in Elderly Women and DHEA or Testosterone in Elderly Men. Nair KS, Rizza RA, O'Brien P, et al. The New England Journal of Medicine. 2006;355(16):1647-59. doi:10.1056/NEJMoa054629.